Immuno-Oncology for Solid Tumors: Overcoming Barriers in the Tumor Microenvironment

The solid tumor microenvironment is immunosuppressive and poses a significant obstacle to achieving clinical success with various immunotherapies. Most notably, immune checkpoint pathways, including PD-1, PD-L1, and CTLA-4, allow tumors to evade the body’s usual immune reaction, leading to disease progression. Checkpoint blockade via monoclonal antibodies results in augmented T-cell activation and proliferation to enhance the anti-tumor immune response and has revolutionized the field, but not all patients are candidates and severe adverse effects persist. Therefore, the development of other approaches, such as antibody-drug conjugates, vaccines, and adoptive cell-based therapies, has surged. Recent advances in immunotherapy have certainly produced enhanced treatment options for solid tumors, but obstacles to their mainstream use remain. To explore novel strategies in immuno-oncology for solid tumors, The Scientist is bringing together a panel of experts to share their research and insights into what it may take to overcome the barriers in the tumor microenvironment.

Topics to be Covered

Immunotherapy in Lung Cancer
Adoptive Immunotherapy: Overcoming Barriers Against Solid Tumors with Potent T cells

Event Overview

Register Now

Immuno-Oncology for Solid Tumors: Overcoming Barriers in the Tumor Microenvironment